Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

6.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.0K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

255
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
255
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

184
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
184

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Terbium-161 might be superior to lutetium-177 for oligometastases - Authors' reply.

The Lancet. Oncology·2026
Same author

Evaluation of PET/CT Artificial Intelligence Image Reconstructions VS Harmonized Clinical Reconstruction.

Zeitschrift fur medizinische Physik·2026
Same author

Anti-Yo related pure sensory ganglionopathy: a rare paraneoplastic entity.

Acta neurologica Belgica·2026
Same author

[<sup>177</sup>Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study.

The Lancet. Oncology·2026
Same author

Head to head comparison of [<sup>18</sup>F]SiTATE versus [<sup>18</sup>F]DOPA-PET in patients with neuroendocrine tumors.

European journal of nuclear medicine and molecular imaging·2025
Same author

Higher thyroid hormone levels and cancer.

Vitamins and hormones·2025

Related Experiment Video

Updated: Oct 3, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

419

PSMA PET in Imaging Prostate Cancer.

Ioannis Tsechelidis1, Alexis Vrachimis1,2

  • 1Department of Nuclear Medicine, German Oncology Center, University Hospital of the European University, Limassol, Cyprus.

Frontiers in Oncology
|February 14, 2022
PubMed
Summary

Prostate-specific membrane antigen (PSMA) PET imaging shows superior accuracy in detecting prostate cancer extent compared to traditional methods, especially for high-risk patients and those with biochemical recurrence. Further research will define its role in intermediate-risk cases.

Keywords:
PET/CTbiochemical failure (BF)restagingstagingtheranostics

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K

Related Experiment Videos

Last Updated: Oct 3, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

419
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.4K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.1K

Area of Science:

  • Nuclear Medicine
  • Radiology
  • Oncology

Background:

  • Accurate staging of prostate cancer is crucial for effective treatment planning and improved patient survival.
  • Current imaging guidelines rely on conventional techniques like CT, MRI, and bone scintigraphy (BS).
  • Prostate-specific membrane antigen (PSMA) PET is a novel nuclear medicine imaging modality with emerging potential.

Purpose of the Study:

  • To evaluate the diagnostic performance of PSMA PET in determining prostate cancer extent.
  • To compare PSMA PET with conventional imaging techniques (CT, MRI, BS).
  • To assess the utility of PSMA PET across different risk groups and in cases of biochemical failure.

Main Methods:

  • Review of studies comparing PSMA PET with conventional imaging for prostate cancer staging.
  • Analysis of PSMA PET's impact on treatment decisions in various patient cohorts.
  • Evaluation of current evidence regarding PSMA PET's role in clinical guidelines.

Main Results:

  • PSMA PET outperforms combined CT and BS in high-risk prostate cancer patients.
  • PSMA PET is recommended for patients with biochemical failure, regardless of castration status.
  • PSMA PET can reveal more extensive disease than initially suspected, influencing treatment strategies.

Conclusions:

  • PSMA PET demonstrates significant advantages over conventional imaging for specific prostate cancer patient groups.
  • Its role in intermediate-risk patients requires further investigation and clinical trials.
  • PSMA PET is poised to become a valuable tool, potentially a gold standard, in prostate cancer management.